NCT05283330
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
StatusActive, Not Recruiting
PhasePhase 1
SponsorOrano Med Theranostics, SAS
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 11 versions: 10 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 26 words Show 4 more changesShow less
- Enrollment closed, study ongoing
- Secondary endpoints: details revised at 7 of 12 entries
- Site details revised at 8 of 8 sites
- Publications: details revised at 2 of 2 entries
- Notable Sponsor changed: Orano Med LLC to Orano Med Theranostics, SAS
- Trial sites expanded: 4 → 8 locations
- Minor Site details revised at 1 of 4 sitesv9
Notable Eligibility criteria shortened, about 294 wordsv7 Show 5 more changesShow less
- Enrollment target: 55 to 48
- Primary completion date: Aug 2026 to Jan 2027
- Study completion date: Aug 2027 to May 2032
- Secondary endpoints: 7 to 12
- Study description shortened, about 7 words
Notable Enrollment target: 30 to 55v6 Show 5 more changesShow less
- Primary completion date: Aug 2024 to Aug 2026
- Eligibility criteria expanded, about 589 words
- Study completion date: Jan 2025 to Aug 2027
- Secondary endpoints: details revised at 1 of 7 entries
- Study description expanded, about 28 words
Show 4 earlier versionsHide 4 earlier versions
- Notable Enrollment target: 50 to 30
- Eligibility criteria expanded, about 7 words
- Study sites revised (4)
- Study title shortened, about 1 word
- Minor Study sites revised (4)v4
- Minor Site contacts updated at 1 of 4 sitesv3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of May 2022 to Dec 22, 2022
- Study sites: 0 to 4
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
To determine the Recommended Phase 2 Dose (RP2D) of ²¹²Pb-DOTAM-GRPR1
Timeframe: 14 months
Secondary (6)
To assess the safety and tolerability of 212Pb-DOTAM-GRPR1.
To assess the safety and tolerability of 203Pb-DOTAM-GRPR1.
To assess PK of ²¹²Pb-DOTAM-GRPR1
To evaluate the preliminary antitumor activity of 212Pb-DOTAM-GRPR1.
To evaluate the preliminary antitumor activity of 212Pb-DOTAM-GRPR1
Show 1 moreShow less
To evaluate the preliminary antitumor activity of 212-PbDOTAM-GRPR1.
Arms and interventions
²¹²Pb-DOTAM-GRPR1Experimental
In the dose escalation portion, a classic 3+3 design will be utilized for the SAD cohorts and a Boin design for the MAD cohorts. Doses will be increased by approximately 30% in subsequent cohorts. The maximum total dose that may be administered to a subject per cycle is 5.5 mCi +/- 10%.
Drugs: ²¹²Pb-DOTAM-GRPR1
Sites
8 sites in 1 country